Granules US arm gets clean USFDA report for Chantilly facility

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

GRANULES · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.5%Reaction day

₹781.00

prior close

₹789.35

announcement price

In-mkt

timing

Nifty Smallcap 250market · index membership as recorded later (tracked since Jun 2026)+0.0%+1.5% vs market

Pharmaceuticals peers, median of 163sector-0.0%+1.5% vs sector

On the reaction day the stock moved 1.5 pts more than Nifty Smallcap 250 and 1.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.2

10m

+0.1

15m

+0.0

30m

-0.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.5+0.0+1.5-0.0+1.5

Next day

+0.8+0.6+0.2+0.2+0.6

+0.6+0.6-0.1+0.5+0.0

-1.7-1.2-0.5-0.2-1.5

-1.8+0.2-2.0+0.7-2.6

-2.2-1.0-1.2+0.1-2.3

-2.0+0.8-2.8+0.9-2.8

15d

-1.1+4.9-6.0+4.6-5.6

+6.6+6.2+0.4+6.5+0.2

+7.9+7.2+0.7+6.3+1.6

+9.5+8.8+0.6+7.9+1.6

UpDownMarket · Nifty Smallcap 250Sector · Pharmaceuticals peers, median of 163Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Granules India announced its US subsidiary Granules Pharmaceuticals Inc received a USFDA Establishment Inspection Report (EIR) with Voluntary Action Indicated (VAI) classification for its Chantilly, Virginia facility. The inspection ran from March 30 to April 3, 2026, with four Form 483 observations issued. VAI is the most favourable outcome, meaning no further regulatory action is required and the facility is deemed compliant.

Likely market impact

Removes regulatory uncertainty for the US facility, allowing uninterrupted production and supply of US-marketed drugs.